Zealand Pharma has entered into a strategic collaboration with Generate Biomedicines, agreeing to an upfront payment of $30 million. This partnership aims to develop AI-designed metabolic therapies. The total value of the deal could reach $1.2 billion, contingent upon the achievement of various milestones. AI
IMPACT This collaboration highlights the increasing use of AI in pharmaceutical research for developing novel therapies, potentially accelerating drug discovery timelines.
RANK_REASON Significant funding and partnership for AI-driven drug discovery. [lever_c_demoted from significant: ic=1 ai=0.7]
Read on Mastodon — mastodon.social →
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →